Benazepril-d5 (hydrochloride) (Synonyms: CGS 14824A-d5) |
| Catalog No.GC46913 |
An internal standard for the quantification of benazapril
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1279026-26-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Benazepril-d5 is intended for use as an internal standard for the quantification of benazepril . Benazepril is a prodrug of the angiotensin converting enzyme (ACE) inhibitor benazeprilat .1 It is metabolized to benazeprilat by hepatic esterases. Benazepril inhibits the in vitro enzymatic activity of partially purified ACE isolated from rabbit lung (IC50 = 2 nM).2 It decreases the triglyceride and total cholesterol levels in normotensive rats when administered at a dose of 30 mg/kg and decreases aortic atherosclerosis in cholesterol-fed rabbits when administered at a dose of 3 mg/kg per day.3 Benazepril (0.1-10 mg/kg per day) reduces blood pressure in spontaneously hypertensive rats.4 It also decreases proteinuria in cats with chronic kidney disease when administered at doses ranging from 0.5 to 1 mg/kg per day.5 Formulations containing benazepril have been used to treat hypertension, congestive heart failure, and chronic kidney disease in both human and veterinary medicine.
1.Toutain, P.L., and LefÈbvre, H.P.Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitorsJ. Vet. Pharmacol. Ther.27(6)515-525(2004) 2.Ksander, G.M., Erion, M., Yuan, A.M., et al.Dual angiotensin converting enzyme/thromboxane synthase inhibitorsJ. Med. Chem.37(12)1823-1832(1994) 3.Yamamoto, S., Takemori, E., Hasegawa, Y., et al.General pharmacology of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride. Effects on cardiovascular, visceral and renal functions and on hemodynamicsArzneimittelforschung41(9)913-923(1991) 4.Watthey, J.W.H., Stanton, J.L., Desai, M., et al.Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzymeJ. Med. Chem.28(10)1511-1516(1985) 5.King, J.N., Gunn-Moore, D.A., Tasker, S., et al.Tolerability and efficacy of benazepril in cats with chronic kidney diseaseJ. Vet. Intern. Med.20(5)1054-1064(2006)
| Cas No. | 1279026-26-4 | SDF | |
| Synonyms | CGS 14824A-d5 | ||
| Canonical SMILES | O=C(OCC)[C@@H](N[C@H]1CCC2=C(C=CC=C2)N(CC(O)=O)C1=O)CCC3=C([2H])C([2H])=C([2H])C([2H])=C3[2H].Cl | ||
| Formula | C24H23D5N2O5.HCl | M.Wt | 466 |
| Solubility | DMSO: slightly soluble,Ethanol: slightly soluble,Methanol: slightly soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1459 mL | 10.7296 mL | 21.4592 mL |
| 5 mM | 0.4292 mL | 2.1459 mL | 4.2918 mL |
| 10 mM | 0.2146 mL | 1.073 mL | 2.1459 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *